Navigation Links
Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
Date:9/23/2009

SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy.

"Late stage prostate cancer remains an obvious and large unmet clinical need," said David Hung, M.D., president and chief executive officer of Medivation. "However, many earlier stage prostate cancers are also inadequately treated, as evidenced by their progression, often rapidly, to late stage disease. Our ultimate goal is to develop MDV3100 for the broadest possible spectrum of prostate cancer disease states. The first step is to develop this product candidate for patients with the most advanced disease and in greatest need. However, we believe that patients with earlier-stage disease may also benefit given the attributes of MDV3100, and we look forward to expanding development to include those patients in potential future studies."

The randomized, placebo-controlled, double-blind, multi-national AFFIRM trial is expected to enroll approximately 1,200 patients at sites in the United States, Canada, Europe, South America, Australia and South Africa. The primary endpoint of the trial is overall survival; secondary endpoints include progression-free survival, safety and tolerability. This trial will evaluate MDV3100 at a dose of 160 mg taken orally once daily versus placebo.

Information about patient eligibility and enrollment can be obtained by calling the AFFIRM study hotline toll-free at 1-888-782-3256.

<
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
2. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
3. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
5. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
6. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
7. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
8. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
9. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
10. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
11. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Sarnova, parent ... launch of the new www.tri-anim.com website, ... specialty healthcare distributor of respiratory, anesthesia and other ... The site has many new ... experience, making online shopping and ordering easier and ...
(Date:3/2/2015)... , March 2, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ Insulin ... announced public offering of common stock have exercised their ... common stock at a price to the public of ... the offering is expected to be $64.8 million, after ...
(Date:3/2/2015)... FRANCISCO, Calif. , March 2, 2015 /PRNewswire/ ... the treatment of cancer, today announced the creation ... leading researchers and clinicians in the fields of ... The new advisory boards will provide guidance ... owned pipeline of precision immunotherapies and Probody drug ...
Breaking Medicine Technology:Tri-anim Health Services Launches New Website Featuring Improved Product Selection and Ease of Ordering 2Tri-anim Health Services Launches New Website Featuring Improved Product Selection and Ease of Ordering 3Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 3CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3
... spans paleogenomics, paired-end mapping, and ... gene expression ... a Roche,company, is the subject of three ground-breaking studies published ... Sequencer(TM),system. The studies, entitled "Paired-End Mapping Reveals Extensive Genomic,Structural Variation ...
... SOPHIA ANTIPOLIS, France, Oct. 2 NicOx ... promising clinical and,preclinical results from its collaboration ... Congress of Dermatology, in Buenos Aires, Argentina.,These ... a prototype compound, showing,the potential for improved ...
Cached Medicine Technology:Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week 2Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week 3Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week 4NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology 2NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology 3
(Date:3/2/2015)... Cutler Integrative Medicine a leader in bringing ... cutting-edge tips to bring about self-renewal. A 30 day ... by first cleaning house. According to Dr. Cutler, ... Toxic.” Between environmental toxins like heavy metals, people’s food ... high stress levels, we all have a level of ...
(Date:3/2/2015)... Today the Brain Injury Association of America (BIAA) officially kicked ... support the more than 5.3 million Americans who are living ... nation in observing Brain Injury Awareness Month by conducting an ... the 2015 to 2017 campaign is: Not Alone. , ... general public about the incidence of brain injury and the ...
(Date:3/2/2015)... Surgeons at the Forbes Hospital ... are exploring an innovative use of Google Glass ... Reminder (VIZR), to assist in the care of critically ... a wearable technology with an optical head-mounted display that ... with the Internet via natural language voice commands. , ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 1% for ... will celebrate the addition of over 25 new business members ... Expo West in Anaheim, Calif. 1% for the Planet welcomes ... which will join through its nut butter line. , Food ... and dispose of waste - continues to be a complex ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 GBCHealth, ... of catalyzing private sector activities and investments in ... recently elected four new members to serve on ... Dr. Paul Farmer, Chief Strategist and Co-founder of ... Harvard University; Dr. Huma Abbasi, General Manager of ...
Breaking Medicine News(10 mins):Health News:Skin and Wellness Power Couple give Quick Tips to Self-Renewal for Spring 2Health News:Brain Injury Association of America Launches “Not Alone” Campaign for Brain Injury Awareness Month 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:1% For the Planet Members Shine Light on Food as Environmental Issue at Expo West 2Health News:1% For the Planet Members Shine Light on Food as Environmental Issue at Expo West 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 2Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 3Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 4Health News:Dr. Paul Farmer and Leaders from Chevron, Johnson & Johnson and Merck Join GBCHealth’s Board of Directors 5
... Launched earlier this month,as a members-only benefit, ... to its AVMA Collections to the general public,expanding ... and up-to-date,veterinary medical information., AVMA Collections was ... organized by topic/subject from the Journal of the,American ...
... Duane Reade Holdings, Inc. today,announced that David D,Arezzo, ... the Company to assume a senior management,position at a ... on April 17, 2008., The Company has initiated ... will move swiftly to identify another high caliber executive,to ...
... toxic, so strategy should be abandoned, study says , , ... not improve the survival rate of patients with small ... , Testing on 140 patients in a randomized trial ... tumor size between groups receiving either standard or high ...
... having friends and mates, survey shows , , WEDNESDAY, April ... 15 million Americans from leading normal social and romantic ... many isolated, ashamed and often misdiagnosed. Thirty-six percent of ... years or more before seeking help, the Anxiety Disorders ...
... -- A new study underscores the need for seniors to ... Building on a 2003 study that found that healthy seniors ... researchers have now discovered that the later in life a ... persons finances. , The study found that when seniors develop ...
... Ritalin, Provigil, beta blockers used to boost focus, ... (HealthDay News) -- One in five respondents to ... drugs" -- such as ADHD and heart medications ... , The most popular drug was Ritalin (methylphenidate), ...
Cached Medicine News:Health News:AVMA Opens Online Resource to General Public 2Health News:Duane Reade Holdings, Inc. Announces Resignation of Chief Marketing Officer 2Health News:High-Dose Chemo Fails Against Small Cell Lung Cancers 2Health News:15 Million Americans Suffer From Social Anxiety Disorder 2Health News:15 Million Americans Suffer From Social Anxiety Disorder 3Health News:Study: Health 'shocks' diminish wealth more later in life 2Health News:Study: Health 'shocks' diminish wealth more later in life 3Health News:Professionals Use Drugs to Sharpen Their Minds, Survey Finds 2Health News:Professionals Use Drugs to Sharpen Their Minds, Survey Finds 3
... 3800 and 3900/P pulse oximeters are ... proprietary clinical patient motion algorithm from ... performance:, ,The 3800 and 3900 ... environmental/ mechanical stress testing such as ...
... anesthesia monitor., ,The Cardiocap/5 is ... use in the operating room, ambulatory ... The Cardiocap/5 offers full vital signs ... oxygenation and circulation to advanced airway ...
... of clinical information. , ,S/5 Clinical ... connectivity solutions that help you and your ... care. You will have access to essential ... it with your care team and specialists, ...
... Releasing the power of clinical information. , ... generation of clinical connectivity solutions that help ... effective, high-quality patient care. You will have ... able to share it with your care ...
Medicine Products: